- Stocks
- Healthcare
- NASDAQ: OCUL

Price (delayed)

$13.51

Market cap

$1.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$876.17M

Ocular Therapeutix's gross margin has surged by 72% YoY and by 2.6% QoQ

Ocular Therapeutix's gross profit has increased by 30% QoQ

Ocular Therapeutix's quick ratio has surged by 71% YoY but it has decreased by 10% QoQ

The net income has declined by 44% year-on-year but it has increased by 16% since the previous quarter

What are the main financial stats of OCUL

Market
Valuations
Earnings

Shares outstanding

76.29M

Market cap

$1.03B

Enterprise value

$876.17M

Price to earnings (P/E)

N/A

Price to book (P/B)

12.32

Price to sales (P/S)

46.43

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

39.58

Revenue

$22.14M

EBIT

-$124.19M

EBITDA

-$121.5M

Free cash flow

-$52.81M

Per share
Balance sheet
Liquidity

EPS

-$2.13

Free cash flow per share

-$0.69

Book value per share

$1.1

Revenue per share

$0.29

TBVPS

$3.19

Total assets

$243.04M

Total liabilities

$159.63M

Debt

$56.61M

Equity

$83.41M

Working capital

$200.7M

Debt to equity

0.68

Current ratio

8.31

Quick ratio

8.19

Net debt/EBITDA

1.27

Margins
Efficiency
Dividend

EBITDA margin

-548.9%

Gross margin

90.3%

Net margin

-591.8%

Operating margin

-300.2%

Return on assets

-73.8%

Return on equity

-326%

Return on invested capital

-195.3%

Return on capital employed

-57.6%

Return on sales

-561%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ocular Therapeutix stock price performed over time

Intraday

0.15%

1 week

-6.51%

1 month

-3.43%

1 year

51.46%

YTD

-34.73%

QTD

-17.67%

How have Ocular Therapeutix's revenue and profit performed over time

Revenue

$22.14M

Gross profit

$19.98M

Operating income

-$66.46M

Net income

-$131M

Gross margin

90.3%

Net margin

-591.8%

Ocular Therapeutix's operating margin has soared by 77% YoY and by 17% from the previous quarter

Ocular Therapeutix's gross margin has surged by 72% YoY and by 2.6% QoQ

The net margin has soared by 59% YoY and by 34% from the previous quarter

The net income has declined by 44% year-on-year but it has increased by 16% since the previous quarter

What is Ocular Therapeutix's growth rate over time

What is Ocular Therapeutix stock price valuation

P/E

N/A

P/B

12.32

P/S

46.43

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

39.58

The company's EPS rose by 17% QoQ but it fell by 11% YoY

The equity is up by 10% since the previous quarter

The stock's P/S is 46% below its 5-year quarterly average of 85.8 and 20% below its last 4 quarters average of 58.3

The revenue has grown by 27% from the previous quarter

How efficient is Ocular Therapeutix business performance

Ocular Therapeutix's return on equity has surged by 95% YoY and by 65% QoQ

OCUL's return on invested capital has dropped by 63% year-on-year but it is up by 13% since the previous quarter

The company's return on sales has surged by 58% YoY and by 34% QoQ

The return on assets has grown by 36% since the previous quarter and by 33% year-on-year

What is OCUL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for OCUL.

How did Ocular Therapeutix financials performed over time

Ocular Therapeutix's total assets is 52% higher than its total liabilities

Ocular Therapeutix's total liabilities has soared by 91% YoY but it has decreased by 14% from the previous quarter

Ocular Therapeutix's quick ratio has surged by 71% YoY but it has decreased by 10% QoQ

The debt is 32% less than the equity

The company's debt to equity has surged by 112% YoY but it fell by 12% QoQ

The equity is up by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.